Fact Source: Financial Supervisory Service DART / 2026-02-11
Disclosure Type: Decision on Convening of General Shareholders’ Meeting
💡 3-Second Summary
Samsung Biologics has resolved to convene its 15th Annual General Meeting (AGM) on March 20, 2026. The upcoming meeting will vote on major agendas including the re-election of Inside Directors John Rim and Kyun No, the appointment of legal expert Kim Jung-yeon as an Independent Director, and amendments to the articles of incorporation.
📊 1. [Key Disclosure Content & Major Figures Summary]
- AGM Schedule & Venue: March 20, 2026 at 09:00 KST / Room 305, 3rd Floor, Songdo Convensia, Incheon, South Korea.
- Reporting Items: Report on transactions with interested parties, Audit report, Business report, and Report on the operational status of the internal accounting control system.
- Agendas to be Voted Upon:
- Agenda No. 1: Approval of the 15th Fiscal Period (2025.1.1~12.31) Financial Statements.
- Agenda No. 2: Amendments to the Articles of Incorporation (Sub-agenda 2-1: Refinement on exclusion of cumulative voting; Sub-agenda 2-2: Reflecting Commercial Act revisions).
- Agenda No. 3: Election of Directors (Re-election of Inside Director John Rim and Inside Director Kyun No for a 3-year term each).
- Agenda No. 4: Election of Independent Director Kim Jung-yeon becoming an Audit Committee member (New appointment, 3-year term).
- Agenda No. 5: Approval of Director Remuneration Limit.
- Nominee Profiles:
- John Rim (Inside Director Nominee): Current CEO & President of Samsung Biologics (Former CFO at Genentech, VP at Roche Global Product Development Procurement).
- Kyun No (Inside Director Nominee): Current Executive VP & Head of EPCV Center at Samsung Biologics.
- Kim Jung-yeon (Independent Director/Audit Committee Nominee): Current Professor at Ewha Womans University School of Law (Former Attorney at Kim & Chang, Second Secretary at the Ministry of Foreign Affairs and Trade; plans to resign from current independent directorship at Hankook Tire & Technology prior to this AGM).
- Board Resolution: Resolved on 2026-02-11 with all 4 independent directors present. This filing does not address financial performance changes; hence, specific drivers for earnings fluctuations are not stated.
📈 2. [Expert View: What This Disclosure Means for Investors]
This filing serves as a preliminary notice detailing Samsung Biologics’ upcoming management alignment and corporate governance adjustments. A key fact for investors is the proposed 3-year term extension for current CEO John Rim and Executive VP Kyun No, signaling a strategy to maintain operational continuity for its ongoing capital-intensive domestic and international CAPEX projects.
Additionally, the proposed updates to the articles of incorporation regarding the refinement of cumulative voting exclusions and Commercial Act alignments, alongside the nomination of legal academic Kim Jung-yeon, indicate an effort to streamline board operations and reinforce corporate compliance. Because this disclosure is a preliminary notice for an upcoming assembly, the final adoption of these items and the definitive financial figures will be decided during the actual AGM on March 20. Investors should treat this filing as a roadmap and focus on how the finalized board structure and statutory modifications may carry a potential impact on corporate governance.
📝 Editor’s Comment (by K-STOCK Editor)
The 15th AGM convening notice from Samsung Biologics focuses clearly on securing executive leadership continuity and adjusting its governance framework. The proposed re-election of CEO John Rim, who possesses extensive global financial experience at big pharma peers such as Genentech and Roche, carries a potential impact that provides structural stability for the company’s long-term strategic direction. Furthermore, the nomination of Professor Kim Jung-yeon, with her background at the Ministry of Foreign Affairs and Kim & Chang, reflects an intention to enhance the board’s regulatory compliance oversight. Since this public notice only outlines proposed agendas prior to voting, global investors should await the finalized outcomes of the March 20 meeting before assessing the structural alignment of the newly established 7-member board.
📢 Disclaimer & Source Information
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the individual investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
